View Older Stories
-
SCIEX launches novus V55 mass spectrometer with AI-enabled software
-
Citi Resumes Danaher (DHR) at Buy
-
China holds roundtable with over 50 foreign pharmaceutical firms
-
Henry Schein elects William Daniel as independent chairman
-
RBC Capital Assumes Danaher (DHR) at Outperform
-
Masimo shareholders approve $180 per share Danaher acquisition
-
Danaher (DHR) call put ratio 1 call to 3.3 puts
-
Danaher (DHR) PT Lowered to $255 at Morgan Stanley
-
Danaher (DHR) Reiterated at Buy by Stifel After a 'Mixed' Start to the Year
-
Danaher (DHR) PT Lowered to $235 at Guggenheim
-
Barclays Reiterates Overweight Rating on Danaher (DHR)
-
Danaher (DHR) PT Lowered to $240 at TD Cowen
-
Danaher (DHR) PT Raised to $232 at Evercore ISI
-
Danaher falls on revenue miss despite earnings beat
-
Danaher (DHR) Tops Q1 EPS by 12c, raises guidance
-
Stocks expected to have increasing option volume: DHR ISRG CB COF NOC MMM DHI IBKR HAL NTRS WAL FIG
-
Danaher (DHR) call put ratio 1.3 calls to 1 put into quarter results
-
Evercore: ' Latest Survey Work Positions 2026 As Better Year For Biopharma Spending'
-
Danaher Nears $10 bln Deal To Acquire Masimo- FT
-
Danaher board member Jessica Mega retires from director role
-
TD Cowen on Danaher (DHR): '4Q Details & Guide Pressures Shares'
-
KeyBanc Reiterates Overweight Rating on Danaher (DHR)
-
Danaher (DHR) PT Raised to $265 at Jefferies
-
Danaher (DHR) PT Raised to $254 at Evercore ISI
-
Danaher (DHR) PT Raised to $270 at BofA Securities
-
Increasing unusual put option volume: LRN BRBR APH GOSS IAG EAT GLW LWLG STZ XRX LOGI NXT DHR AQST
-
Danaher beats Q4 expectations as bioprocessing business shows strength
-
Danaher (DHR) Tops Q4 EPS by 9c; offers outlook
-
Danaher (DHR) call put ratio 1 call to 1.2 puts into quarter results
-
Danaher expects mid-single digit revenue growth in fourth quarter
-
KeyBanc: 'We Highlight Danaher (DHR) Potential and EBITDA Upside'
-
Goldman Sachs starts Life Sciences Tools coverage, rates these 3 stocks at Buy
-
Goldman Sachs Starts Danaher (DHR) at Buy
-
KeyBanc on Life Sciences Tools & Services: 'We Highlight Our Favored 2026 "Tools" Stocks'
-
Danaher (DHR) call put ratio 1 call to 2.9 puts
-
Morgan Stanley Starts Danaher (DHR) at Overweight, Top Pick
-
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Danaher Corporation (DHR) as Securities Fraud Class Action Survives Motion to Dismiss
-
Danaher (DHR) PT Raised to $260 at TD Cowen
-
Danaher (DHR) Tops Q3 EPS by 17c
-
Danaher (DHR) call put ratio 1 call to 1.3 puts into quarter results
-
Rothschild Redburn Downgrades Danaher (DHR) to Neutral
-
KeyBanc Takeaways from This Year's BioProcess International Conference
-
Danaher authorizes buyback of up to 35 million shares
-
Stifel Reiterates Buy Rating on Danaher (DHR)
-
Danaher (DHR) Tops Q2 EPS by 16c; lifts FY EPS forecast
-
Danaher (DHR) call put ratio 1 call to 1 put into the expected release of results
-
Danaher (DHR) PT Raised to $226 at Baird, 'see potential upside in Biotechnology and Diagnostic'
-
Scotiabank Upgrades Danaher (DHR) to Sector Outperform
-
Supreme Court Braidwood ruling is positive for DX names like DHR, EXAS, NTRA, HOLX, QDEL - RBC Capital
-
Danaher (DHR) Appoints Martin Stumpe as Chief Technology and AI Officer

